Planview Unveils New Visual Identity at 2019 Global SAFe Summit
2.10.2019 16:05:00 EEST | Business Wire | Press release
Today, at the 2019 Global SAFe Summit in San Diego, California, Planview unveiled a bold new corporate visual identity. Since 1989, Planview has been on the forefront of providing award-winning enterprise solutions for managing work and resources. Now, Planview enters this next chapter as the premier platform for enabling every organization to seamlessly transform strategy to delivery in today’s changing world of work.
“Planview has been on a remarkable transformational journey with industry-leading growth and capability expansion, and it is an exciting day with the launch of our new corporate identity,” said Planview CEO Greg Gilmore. “Over the past year we have rewired Planview – today we are a bold, agile enterprise solutions leader that delivers breadth and scale for addressing all the ways organizations and teams work. The new Planview logo and visual design truly embody who we have become and where we are heading with our customers.”
The company’s new logo mark is inspired by forward-looking transformational leaders who – like peregrine falcons – require speed, agility, and keen vision to change altitude and swoop quickly in response to business and market changes and to help every team deliver value aligned to organizational strategy. The shades of red in the falcon symbolize the heroic journey these leaders and organizations must traverse in pursuit of bold advancements.
On October 2 and 3 at the Global SAFe Summit, attendees can experience how Planview solutions enable them to realize Agile at scale and make the project to product shift in the changing world of work. Planview will also demonstrate its new Agile costing solution, which eliminates manual time reporting and reduces the financial challenges of Agile at scale. By breaking down silos, connecting teams, integrating portfolios, and providing executive level visibility enterprise-wide, Planview solutions ensure organizations can plan and scale more effectively to deliver customer value faster.
Next week, Planview is hosting Planview Horizons – its 22nd annual customer conference – October 8-10 at the JW Marriott in Austin, Texas. “We really look forward to celebrating this new chapter in the company’s history with our customers and partners at Planview Horizons 2019. They are at the center of everything we do, and it is an honor to be by their sides for every one of their transformational journeys,” affirmed Gilmore.
About Planview
There is a bold new way of working, where every individual and team can move seamlessly from strategy to successful delivery – every day. Planview makes it possible. We empower you with a single line of sight across your entire organization and help every team collaborate to create value. Imagine realizing Agile at scale, creating a culture of innovation, and making the product shift. You are a change agent. So are we. For more information, visit www.planview.com.
Planview® and Planview Horizons® are registered trademarks of Planview, Inc.
All other trademarks listed herein are owned by their respective companies.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20191002005203/en/
Contact information
Planview, Inc.
Karoline McLaughlin
kmclaughlin@planview.com
+1 512 596 3493
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From AI to Autonomous Networks: Mobileum Spark Highlights the Next Frontier of Telecom Intelligence15.10.2026 10:00:00 EEST | Press release
Mobileum Inc. ("Mobileum"), a leading global provider of telecom analytics and network solutions, brought together telecom operators and industry leaders during its Mobileum Spark events series in Lisbon (Portugal) and Frankfurt (Germany), to explore how Artificial Intelligence (AI), Agentic AI and automation are transforming network operations and accelerating the evolution toward autonomous networks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261015172815/en/ Telecom operators, industry leaders, and Mobileum experts at Mobileum Spark 2026. Focused on Risk Management & Fraud Prevention and Network Testing & Assurance, the events featured customer-led discussions, expert insights, and real-world use cases demonstrating how AI and advanced automation are helping operators address increasing network complexity, strengthen fraud prevention, improve service assurance, and drive operational efficiency. A central theme across
Merz Therapeutics Announces Completion of Recruitment in Two Phase III Trials Investigating XEOMIN ® (incobotulinumtoxinA) for Migraine Prevention15.10.2026 09:00:00 EEST | Press release
Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, today announced the completion of patient recruitment in two global Phase III clinical trials, MINT-E (NCT07018700) and MINT-C (NCT07018713), evaluating the efficacy and safety of XEOMIN® (incobotulinumtoxinA) for the prevention of episodic and chronic migraine in adults. The trials recruited approximately 1800 adults across 109 study sites in North America and Europe. Migraine affects around 1.1 billion people worldwide, posing a significant burden on patients, society and healthcare systems.1 Both trials are evaluating the change in monthly migraine days from baseline to Month 6 as the primary endpoint. Secondary endpoints include changes in monthly headache days, acute medication days and migraine frequency during two-week periods at the end of each injection cycle. “Achieving patient recruitment for both MINT-C and MINT-E six months ahead of plan is an important milestone for our XEOMIN® migraine preven
Tourism Malaysia and Alipay+ Partner to Accelerate Malaysia’s Digital Tourism Transformation15.10.2026 08:10:00 EEST | Press release
Tourism Malaysia and Alipay+, the unified wallet gateway of Ant International, today signed a Memorandum of Understanding (MoU) to accelerate cross-border commerce and digitalise merchant engagement across Malaysia's tourism economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014035900/en/ (From left) Mr Mohd Akbal Setia (Head of VM2026 Secretariat and Senior Director, Advertising & Digital Tourism); Mr Mohd Amirul Rizal Abdul Rahim (Director General, Tourism Malaysia); Mr Danny Chung (General Manager of Alipay+ Global Growth Center and Vice President of Ant International); Mr Michael Guo, Alipay+ General Manager of SEA, South Asia and ANZ, Ant International) As Malaysia welcomes visitors for Visit Malaysia 2026–2027 (VM2026–2027), this partnership merges Tourism Malaysia’s destination marketing with Alipay+’s global wallet ecosystem and AI capabilities. It aims to create a highly intelligent digital journey, connecti
PeDRA 2026: Nemolizumab Phase II Data Show Long-Term Symptom Relief for Children Aged 2 to 11 Years With Moderate-to-Severe Atopic Dermatitis15.10.2026 08:00:00 EEST | Press release
Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new phase II data showing that nemolizumab provided meaningful improvements in itch, sleep disturbance, and quality of life in children aged 2 to 11 years with moderate-to-severe atopic dermatitis, sustained through Week 52.1 The results will be presented at The Pediatric Dermatology Research Alliance (PeDRA) Annual Conference. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261014705800/en/ Up to 25% of children are affected by atopic dermatitis - the most common inflammatory skin disorder in this population - and around one-third of these children have moderate-to-severe disease.11,12 Atopic dermatitis creates a high burden for both the patients and their loved ones, with persistent itch and recurrent skin lesions often disrupting sleep, school, and social confidence.2-8 Despite the high prevalence and significant burden, treatment options are
Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 115.10.2026 03:30:00 EEST | Press release
Takeda (TSE:4502/NYSE:TAK)announced today that ORZEYFUL (oveporexton) is now available in Japan and China for the treatment of narcolepsy type 1 (NT1), providing first access to clinicians to prescribe treatment with the new class of medicine. ORZEYFUL is a first-in-class orexin receptor 2 (OX2R) agonist, in tablet form, designed to treat the underlying orexin deficiency associated with NT1. “We’re excited at the potential to fundamentally change how NT1 is managed across Japan and China,” said Giles Platford, president, International, Takeda. “We’ve heard from patients how ORZEYFUL has improved their daily functioning and quality of life, enormously meaningful outcomes for a condition known to impact many aspects of a person’s life, including work, education and social interactions.”1,2,3,4,5 NT1 is a chronic, rare neurological disease driven by orexin deficiency. People experience a range of symptoms including excessive daytime sleepiness, cataplexy (sudden loss of muscle tone), disr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom